Review of dalbavancin, a novel semisynthetic lipoglycopeptide

Bibliography

• NATIONAL NOSOCOMIALINFECTIONS SURVEILLANCE (NNIS): system report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. (2004) 32(8):470-485.
   PubMed Web of Science ®Google Scholar
• MORAN GJ, KRISHNADASAN A, GORWITZ RJ et al.: Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. (2006) 355(7):666-674.
   PubMed Web of Science ®Google Scholar
• SALGADO CD, FARR BM, CALFEE DF: Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. (2003) 36(2):131-139.
   PubMed Web of Science ®Google Scholar
• NAIMI TS, LEDELL KH, COMO-SABETTI K et al.: Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA (2003) 290(22):2976-2984.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROLAND PREVENTION: Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(26):565-567.
   PubMedGoogle Scholar
• CENTERS FOR DISEASE CONTROLAND PREVENTION: Public health dispatch: vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(40):902.
   PubMedGoogle Scholar
• CENTERS FOR DISEASE CONTROLAND PREVENTION: Brief report: vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR Morb. Mortal. Wkly Rep. (2004) 53(15):322-323.
   PubMedGoogle Scholar
• ZHU W, WEIGEL LM, CLARK NC, MCDOUGAL LK, PATEL JB: Characterization of three Michigan vancomycin-resistant Staphylococcus aureus and vanA plasmids from associated vancomycin-resistant Enterococcus. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (27 – 30 September 2006):C2-608.
   Google Scholar
• COSGROVE SE, CARMELI Y: The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. (2003) 36(11):1433-1437.
   PubMed Web of Science ®Google Scholar
• COSGROVE SE, SAKOULAS G, PERENCEVICH EN, SCHWABER MJ, KARCHMER AW, CARMELI Y: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. (2003) 36(1):53-59.
   PubMed Web of Science ®Google Scholar
• SPELLBERG B, POWERS JH, BRASS EP, MILLER LG, EDWARDS JE Jr: Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. (2004) 38(9):1279-1286.
   PubMed Web of Science ®Google Scholar
• VAN BAMBEKE F: Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. (2004) 4(5):471-478.
   PubMed Web of Science ®Google Scholar
• MALABARBA A, GOLDSTEIN BP: Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. (2005) 55(S2):ii15-ii20.
   PubMed Web of Science ®Google Scholar
• VAN BAMBEKE F, LAETHEM YV, COURVALIN P, TULKENS PM: Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs (2004) 64(9):913-936.
   PubMed Web of Science ®Google Scholar
• MALABARBA A, CIABATTI R: Glycopeptide derivatives. Curr. Med. Chem. (2001) 8(14):1759-1773.
   PubMed Web of Science ®Google Scholar
• KAHNE D, LEIMKUHLER C, LU W, WALSH C: Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev. (2005) 105(2):425-448.
   PubMed Web of Science ®Google Scholar
• BEAUREGARD DA, WILLIAMS DH, GWYNN MN, KNOWLES DJ: Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. (1995) 39(3):781-785.
   PubMed Web of Science ®Google Scholar
• HIGGINS DL, CHANG R, DEBABOV DV et al.: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49(3):1127-1134.
   PubMed Web of Science ®Google Scholar
• JONES RN, BIEDENBACH DJ, JOHNSON DM, PFALLER MA: In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. (2001) 13(3):244-254.
   Google Scholar
• STREIT JM, FRITSCHE TR, SADER HS, JONES RN: Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. (2004) 48(2):137-143.
   PubMed Web of Science ®Google Scholar
• PACE JL, YANG G: Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. (2006) 71(7):968-980.
   PubMed Web of Science ®Google Scholar
• JONES RN, STILWELL MG, SADER HS, FRITSCHE TR, GOLDSTEIN BP: Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. (2006) 54(2):149-153.
   PubMed Web of Science ®Google Scholar
• JONES RN, FRITSCHE TR, SADER HS, GOLDSTEIN BP: Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. (2005) 17(6):593-600.
   PubMed Web of Science ®Google Scholar
• GALES AC, SADER HS, JONES RN: Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect. (2005) 11(2):95-100.
   PubMed Web of Science ®Google Scholar
• LIN G, CREDITO K, EDNIE LM, APPELBAUM PC: Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. (2005) 49(2):770-772.
   PubMed Web of Science ®Google Scholar
• LOPEZ S, HACKBARTH C, ROMANO G, TRIAS J, JABES D, GOLDSTEIN BP: In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J. Antimicrob. Chemother. (2005) 55(S2):ii21-ii24.
   PubMedGoogle Scholar
• BIEDENBACH DJ, FRITSCHE TR, SADER HS, JONES RN: In vitro activity of dalbavancin susceptibility tested against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated in USA medical centers. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (27 – 30 September 2006):E-726.
   Google Scholar
• FLAMM RK, DRAGHI DC, KARLOWSKY JA, SAHM DF: Activity of dalbavancin against clinical isolates of Staphylococci and Streptococci from the US and Europe. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (October 30 – November 2 2004):E-2008.
   Google Scholar
• CUEVAS O, CERCENADO E, GOYANES MJ, MARIN M, CASTELLARES C, BOUZA E: Comparative in vitro activity of dalbavancin against recent clinical isolates of Staphylococcus spp. isolated in Spain. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (17 – 20 September 2006):C2-1141.
   Google Scholar
• GOLDSTEIN EJ, CITRON DM, WARREN YA, TYRRELL KL, MERRIAM CV, FERNANDEZ HT: In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother. (2006) 50(8):2875-2879.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN BP, JONES RN, FRITSCHE TR, BIEDENBACH DJ: Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn. Microbiol. Infect. Dis. (2006) 54(2):83-87.
   PubMed Web of Science ®Google Scholar
• CANDIANI G, ABBONDI M, BORGONOVI M, ROMANO G, PARENTI F: In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. (1999) 44(2):179-192.
   PubMed Web of Science ®Google Scholar
• CARMELI Y, ROTHERMEL C, SHEEHAN D, HOGAN P, MENDELSON M: Analysis of patients with community-acquired methicillin-resistant Staphylococcus aureus in a Phase 3 study of dalbavancin versus linezolid for the treatment of complicated skin and soft tissue infections. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (27 – 30 September 2006):L-1211.
   Google Scholar
• STREIT JM, SADER HS, FRITSCHE TR, JONES RN: Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis. (2005) 53(4):307-310.
   PubMed Web of Science ®Google Scholar
• BOZDOGAN B, ESEL D, WHITENER C, BROWNE FA, APPELBAUM PC: Antibacterial susceptibility of vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. (2003) 52(5):864-868.
   PubMed Web of Science ®Google Scholar
• BOZDOGAN B, EDNIE L, CREDITO K, KOSOWSKA K, APPELBAUM PC: Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob. Agents Chemother. (2004) 48(12):4762-4765.
   PubMed Web of Science ®Google Scholar
• BOWKER KE, NOEL AR, MACGOWAN AP: Antibacterial effect of dalbavancin against MSSA, MRSA and VISA in an in vitro pharmacokinetic system. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (October 30 – November 2 2004):A-1165.
   Google Scholar
• LIN G, SMITH K, EDNIE LM, APPELBAUM PC: Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob. Agents Chemother. (2005) 49(12):5182-5184.
   Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM CV, WARREN Y, TYRRELL K, FERNANDEZ HT: In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob. Agents Chemother. (2003) 47(6):1968-1971.
   Google Scholar
• HEINE HS, BASSETT J, MILLER L: In vitro and in vivo activity of dalbavancin against Bacillus anthracis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (16 – 19 September 2005):F-2079.
   Google Scholar
• FLAMM RK, DRAGHI DC, JONES ME, THORNSBERRY C, SAHM DF: Dalbavancin demonstrates a low potential for in vitro selection of resistance to staphylococci. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (16 – 19 December 2005):C1-1408.
   Google Scholar
• JONES RN, SADER HS, FRITSCHE TR, HOGAN PA, SHEEHAN DJ: Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol. (2006) 44(7):2622-2625.
   PubMed Web of Science ®Google Scholar
• LEIGHTON A, GOTTLIEB AB, DORR MB et al.: Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48(3):940-945.
   PubMed Web of Science ®Google Scholar
• CAVALERI M, COOPER A, NUTLEY MA, STOGNIEW M: Protein binding of dalbavancin using isothermal titration microcalorimetry. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (27 – 30 September 2002):A-1385.
   Google Scholar
• CAVALERI M, RIVA S, VALAGUSSA A et al.: Pharmacokinetics and excretion of dalbavancin in the rat. J. Antimicrob. Chemother. (2005) 55(S2):ii31-ii35.
   PubMed Web of Science ®Google Scholar
• DOWELL JA, BUCKWALTER M, SELTZER E, STOGNIEW M: Dalbavancin penetration in to skin supports once weekly dosing. Clin. Microbiol. Infect. (2005) 11(S2):272 (Abstract P-895).
   Google Scholar
• BULGHERONI A, JABES D, POLLINI W et al.: Dalbavancin uptake by murine macrophages. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (30 October – 2 November 2004):A-1490.
   Google Scholar
• DOWELL J, SELTZER E, STOGNIEW M, DORR MB, FAYOCAVITZ S, KRAUSE D: Dalbavancin dosage adjustments not required for patients with mild renal impairment. Clin. Microbiol. Infect. (2003) 9(S1):291 (Abstract P-1224).
   Google Scholar
• DOWELL JA, SELTZER E, KRAUSE D, HENKEL T: The safety and pharmacokinetics of dalbavancin in subjects with renal impairment or end-stage renal disease. Clin. Microbiol. Infect. (2005) 11(S2):272 (Abstact-P896).
   Google Scholar
• DOWELL JA, SELTZER E, BUCKWALTER M, MARBURY T: The pharmacokinetics of dalbavancin in subjects with mild, moderate or severe hepatic impairment. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (30 October – 2 November 2004):A-19.
   Google Scholar
• BUCKWALTER M, DOWELL JA: Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J. Clin. Pharmacol. (2005) 45(11):1279-1287.
   PubMed Web of Science ®Google Scholar
• ANDES DR, CRAIG WA: In vivo pharmacodynamic characterization of dalbavancin in the murine thigh infection model. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (30 October – 2 November 2004):A-1872.
   Google Scholar
• BOWKER KE, NOEL AR, MACGOWAN AP: Pharmacodynamics of dalbavancin in an in vitro pharmacokinetic system. J. Antimicrob. Chemother. (2006) 58(4):802-805.
   Google Scholar
• JABES D, CANDIANI G, ROMANO G, BRUNATI C, RIVA S, CAVALERI M: Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob. Agents Chemother. (2004) 48(4):1118-1123.
   Google Scholar
• CANDIANI GP, ROMANO G, CAVALERI M, RIVA S, JABES D: Efficacy of a single dalbavancin dose compared with multiple linezolid doses against penicillin-resistant pneumococci in a lobar pneumonia model in the immunocompetent rat. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (22 – 25 December 2001):B-989.
   Google Scholar
• LEFORT A, PAVIE J, GARRY L, CHAU F, FANTIN B: Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob. Agents Chemother. (2004) 48(3):1061-1064.
   PubMed Web of Science ®Google Scholar
• DAROUICHE RO, MANSOURI MD: Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J. Infect. (2005) 50(3):206-209.
   PubMed Web of Science ®Google Scholar
• NORD CE, RASMANIS G, WAHLUND E: Effect of dalbavancin on the normal intestinal microflora. J. Antimicrob. Chemother. (2006) 58(3):627-631.
   PubMed Web of Science ®Google Scholar
• NORD C, SILLERSTROM E, WAHLUND E: New drugs for Gram-positive infections do not select for Clostridium difficile. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (17 – 20 September 2006):K-1016.
   Google Scholar
• JOHNSON DM, FRITSCHE TR, SADER HS, JONES RN: Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int. J. Antimicrob. Agents (2006) 27(6):557-560.
   PubMed Web of Science ®Google Scholar
• SELZER E, DORR MB, GOLDSTEIN BP et al.: Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. (2003) 37(10):1298-1303.
   PubMed Web of Science ®Google Scholar
• JAUREGUI LE, BABAZADEH S, SELTZER E et al.: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. (2005) 41(10):1407-1415.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN BP, SELTZER E, FLAMM R, SAHM D: Dalbavancin phase 3 skin and skin structure studies: pathogens and microbiological efficacy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (16 – 19 December 2005):L-1577.
   Google Scholar
• RAAD I, DAROUICHE R, VAZQUEZ J et al.: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis. (2005) 40(3):374-380.
   PubMed Web of Science ®Google Scholar
• CAMPBELL KCM, KELLY E, TARGOVNIK N et al.: Audiologic monitoring for potential ototoxicity in a Phase 1 clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol. (2003) 14(3):157-168.
   Google Scholar
• SELTZER E, GOLDBERG L, KRAUSE D: Safety of dalbavancin in a clinical development program. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (27 – 30 September 2006):L-1576.
   Google Scholar